Leo Rasche

University Hospital Würzburg
Country flagGermany
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Immune-checkpoint inhibitors (ICIs) benefit patients with advanced melanoma, yet resistance remains common and the myeloid circuits that limit response are incompletely defined. We identify glucocorticoid receptor (GR) signaling in tumor-associated macrophages (TAMs) as a druggable brake on antitumor immunity under PD 1 blockade. Myeloid-specific GR deletion restored immune recognition and overcame anti-PD 1 resistance, resulting in restrained melanoma growth. CITE-seq revealed that GR loss reprogrammed multiple TAM subsets towards interferon-licensed, antigen-presenting, chemokine-producing states, reshaping T cell composition toward cytotoxic effector and tissue-resident memory phenotypes with attenuated exhaustion. Cross-species analyses linked glucocorticoid activity and GR-regulated myeloid and T cell states to clinical response. To therapeutically exploit this axis, we engineered CD169-targeted lipid nanoparticles delivering the GR antagonist mifepristone to TAMs. Targeted GR antagonism re-educated the immune niche, restored T cell stimulatory capacity, and synergized with PD 1 blockade in ICI-refractory melanoma. These data nominate myeloid GR inhibition as a biomarker-guided strategy to enhance ICI efficacy.

Year:

2025

Cell survival of DNMTi pretreated KMS11 cells under BTZ exposure. AlamarBlue assay after 72 hours of incubation with varying concentrations of BTZ (0.5 nM to 4 nM) on DNMTi pretreated cells (48 h 500 nM Aza, 72 h 100 nM Dec) and PI naïve KMS11. No resensitizing effect to PI treatment was observed.

Year:

2025

DNA promoter methylation of a subset of proteasome subunit genes. Heatmap comparing methylation pattern of 35 MM patients and 30 PBMC samples. The methylation degree is given by a color code: red – methylated state, blue – unmethylated state. Each line represents an individual sample, each column a single CpG. The methylation degree is encoded by color with blue for an unmethylated and red for a methylated state. Artificially methylated controls were included. For PSMD5, hypermethylation was only present in MM cells, not in PBMCs. For PSMC2, hypermethylation occurred in both, MM cells and PBMCs, indicating a physiological state probably independent of disease development and progression. In the remaining proteasome subunit genes, no aberrant promoter methylation was detected.

Year:

2025

Patient-derived mutations impair PI response to Carfilzomib and Ixazomib. Cytotoxicity assay and IC50 values of RPMI-8226 MM cell lines harboring two different stably expressed patient-derived mutations in proteasome subunits. The mutants were more resistant to the proteasome inhibitors Carfilzomib and Ixazomib compared to the controls (*) harboring lentivirally-encoded WT sequence of PSMC6/PSMD1. Shown are the means and standard deviations of three independent experiments (biological replicates) and three technical replicates in each experiment. The PSMC6 and PSMD1 expression levels were equivalent for the mutants and the controls.

Year:

2025

Quality check of DBS assays with artificially methylated standard DNAs. DNA standards of 0%, 25%, 50%, 75% and 100% methylation were sequenced with the PSMB5, PSMC2, PSMC5, PSMC6, PSMD1 and PSMD5 DBS assays to confirm assay sensitivity. Results for all investigated DBS amplicons correlated well with the expected curves (P

Year:

2025

Supplemental Figure 1: Swimmer plot of all cases described in the manuscript. Supplemental Figure 2: The 96-mutational profile of the truncal mutations per each of patients that can be timed, revealing a distinct, clonal melphalan signature profile (SBS-MM1/SBS99). Supplemental Figure 3: Additional Cases for which antigen escape timing was not possible.

Year:

2025

Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D , respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy. Significance: Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence. See related commentary by Kauer et al., p. 532

Year:

2025

Introduction Cytokine release syndrome (CRS) is a common adverse event associated with T‐cell redirection therapies (TCRT), including talquetamab, the first GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We describe CRS with talquetamab and implications for clinical practice. Methods Patients without prior TCRT received talquetamab 0.4 mg/kg weekly (QW) and 0.8 mg/kg every other week (Q2W), with two or three step‐up doses, respectively, plus pretreatment with a glucocorticoid, antihistamine, and antipyretic. A separate cohort of patients with prior TCRT received talquetamab at either the QW or Q2W schedule. CRS was graded per American Society for Transplantation and Cellular Therapy criteria and managed per study protocol. Results Across talquetamab QW ( n = 143), Q2W ( n = 145), and prior TCRT ( n = 51) cohorts, most CRS events occurred during step‐up doses and were grade 1 or 2; grade 3 CRS events were rare. Approximately one‐third of patients experienced more than one CRS event. Fewer patients experienced subsequent CRS events if tocilizumab was used versus not used to treat their first CRS event. Overall response rates with talquetamab were similar among patients with and without tocilizumab to manage CRS. Baseline characteristics were not associated with CRS incidence, recurrence, duration, or severity, whereas immune biomarkers showed some trends in association with CRS parameters. Conclusion CRS outcomes with talquetamab were consistent with those seen with other TCRT in RRMM, including teclistamab (BCMA×CD3 bispecific antibody), indicating a similar clinical approach, including early vigilance and prompt treatment of CRS. Trial Registration NCT03399799/NCT04634552

Year:

2025

Extramedullary multiple myeloma (EMD) is associated with low response rates, short progression-free survival, and poor prognosis. CAR T cells and bispecific antibodies (bsABs) have shown efficacy in relapsed myeloma, but it remains uncertain whether one T cell redirection strategy should be preferred. We retrospectively analyzed 80 patients with EMD not adjacent to the bone treated with ide-cel, cilta-cel, teclistamab, or talquetamab at three academic centers in Germany. All patients were heavily pretreated, and a high-risk cytogenetic profile was prevalent in >41% of patients. All cohorts had a median of 5 to 7 prior lines of therapy. The vast majority of patients receiving cilta-cel, ide-cel, or teclistamab were BCMA-naive ( >88%). Response rates after CAR T cell infusion were significantly higher (100% with cilta-cel, 82% with ide-cel) than with bsABs (29% for talquetamab, 36% for teclistamab). Complete resolution of EMD was more frequent after CAR T cell therapies (50% and 41%) than after bsABs (16% and 14%). With a median follow-up of 12.2 months, median (m)PFS was not reached in patients that had received cilta-cel; mPFS was 7.3 months after ide-cel and significantly longer for both CAR T products compared to talquetamab or teclistamab (mPFS 4.0 and 2.6 months). Effective debulking therapy prolonged remissions after CAR T cell infusion compared to no debulking or no response to debulking. Visceral and soft tissue manifestations responded significantly less frequently than EMD in other locations. With significantly higher response rates, deeper remissions, and longer mPFS, our retrospective data suggest CAR T cells may provide a meaningful benefit in EMD.

Year:

2025

Extramedullary multiple myeloma (EMD) is associated with low response rates, short progression-free survival and poor prognosis. CAR T cells and bispecific antibodies (bsABs) have shown efficacy in relapsed myeloma but it remains uncertain whether one T cell redirection strategy should be preferred. We retrospectively analyzed 80 patients with EMD not adjacent to the bone treated with ide-cel, cilta-cel, teclistamab or talquetamab at three academic centers in Germany. All patients were heavily pretreated and a high-risk cytogenetic profile was prevalent in >41% of patients in all cohorts. All cohorts had a median of 5 to 7 prior lines of therapy. The vast majority of patients receiving cilta-cel, ide-cel or teclistamab were BCMA-naive (>91% in all cohorts). Response rates after CAR T cell infusion were significantly higher (93% with cilta-cel, 82% with ide-cel) than with bsABs (47% for talquetamab, 38% for teclistamab, p<0.0001). Complete resolution of EMD was more frequent after CAR T cell therapies (50% and 41%) than after bsABs (16% and 14%, p=0.001). At a median follow-up of 4.6 months, median PFS was not reached after cilta-cel and 11.2 months after ide-cel compared to talquetamab and teclistamab (3.2 and 2.8 months, p=0.03). Visceral and soft tissue manifestations responded significantly less frequent than EMD in other locations (p=0.02). With significantly higher response rates, deeper remissions and longer median PFS, CAR T cells may provide a meaningful benefit in EMD and should be considered preferentially.

Year:

2025

Year:

2024

Year:

2024

Collaborators (20)

Angela Riedel

Junior Group Leader

University of Würzburg

GERMANY
View details

Anders Etzerodt

VIP, Associate Professor

Aarhus University

DENMARK
View details

Paola Neri

University of Calgary

CANADA
View details

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Michal Simicek

Principal Investigator

University of Ostrava

CZECH REPUBLIC
View details

Hermann Einsele

University Hospital Würzburg

GERMANY
View details

María-Victoria Mateos

University Hospital of Salamanca

SPAIN
View details

Thomas Haaf

Julius-Maximilians-Universität

GERMANY
View details

Roman Hajek

University of Ostrava

CZECH REPUBLIC
View details

Bachisio Ziccheddu

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Matthias Goebeler

Chair

University Hospital Würzburg

GERMANY
View details

K. Martin Kortüm

University Hospital Würzburg

GERMANY
View details

Viktor Umansky

Heidelberg University

GERMANY
View details

Nizar J. Bahlis

University of Calgary

CANADA
View details

Antoine-Emmanuel Saliba

Prof

Helmholtz Institute for RNA-based Infection Research

GERMANY
View details

Andreas Kerstan

Assistant professor

Universitätsklinikum Würzburg

GERMANY
View details

Niccolò Bolli

Associate Professor

University of Milan

ITALY
View details

Joaquin Martinez-Lopez

Catedrático de Universidad del área de conocimiento de Medicina

Universidad Complutense de Madrid

SPAIN
View details

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Marc S. Raab

University Hospital Heidelberg

GERMANY
View details